TARS

Tarsus Pharmaceuticals, Inc. [TARS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TARS Stock Summary

Top 10 Correlated ETFs

TARS


Top 10 Correlated Stocks

TARS


In the News

08:03 28 Mar 2024 TARS

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

TARS has reported positive results from three clinical trials of lotilaner in various formulations. TARS plans to discuss the path forward in these new indications with the US Food and Drug Administration. TARS has also reported sales of $13.1M from the first full quarter of Xdemvy's launch as a treatment for Demodex blepharitis.

10:56 28 Mar 2024 TARS

How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%

The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Tarsus Pharmaceuticals, Inc. (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

04:30 28 Mar 2024 TARS

Tarsus to Participate at Upcoming Investor Conferences

IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will participate in the following conferences:

01:01 28 Mar 2024 TARS

Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy

Does Tarsus Pharmaceuticals, Inc. (TARS) have what it takes to be a top stock pick for momentum investors? Let's find out.

05:00 28 Mar 2024 TARS

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m. ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.

05:11 28 Mar 2024 TARS

Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?

Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

12:09 28 Mar 2024 TARS

Tarsus Pharmaceuticals: 3 Clinical Catalysts In The Next 4 Months, Xdemvy Launch Underway

TARS has launched a new drug, Xdemvy, for the treatment of Demodex blepharitis, with net product sales of $1.7M in the first five weeks following launch. TARS has readouts from three clinical trials due in the next four months, with one due in Q4'23. TARS completed a follow-on offering in August, raising net proceeds of $99.4M. TARS had $246.9M in cash at the end of Q3'23.

06:59 28 Mar 2024 TARS

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants David Nakasone - Head, IR Bobak Azamian - Chairman, CEO Aziz Mottiwala - CCO Jeff Farrow - CFO, CSO Conference Call Participants Jason Gerberry - Bank of America Eddie Hickman - Guggenheim Securities Oren Livnat - H.C. Wainwright Frank Brisebois - Oppenheimer Operator Good afternoon and welcome to the Tarsus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call.

06:35 28 Mar 2024 TARS

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, November 9, 2023 to report its third quarter 2023 financial results and provide a corporate update.

11:25 28 Mar 2024 TARS

Rare Stock Picks In September 2023 - From 32 Discerning Analysts

Welcome to another installment of our monthly Rare Buy article where we highlight September investment picks you may have missed. As you know some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come by in today's market environment. Featured in this series are investment ideas published in the last month from analysts who have made ONLY 1 Buy/Strong Buy stock recommendation in the past three months.

TARS Financial details

Company Rating
Neutral
Market Cap
1.26B
Income
-134.36M
Revenue
32.72M
Book val./share
6.17
Cash/share
7.12
Dividend
-
Dividend %
-
Employees
244
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-5.94
Forward P/E
-16.72
PEG
-0.73
P/S
22.87
P/B
2.94
P/C
5.19
P/FCF
-7.16
Quick Ratio
10.89
Current Ratio
11.15
Debt / Equity
0.15
LT Debt / Equity
0.15
-
-
EPS (TTM)
-4.58
EPS next Y
-2.21
EPS next Q
-1.23
EPS this Y
83.33%
EPS next Y
-51.66%
EPS next 5Y
-256.22%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
598.88%
EPS Q/Q
2.34%
-
-
-
-
SMA20
-2.86%
SMA50
54.55%
SMA100
142.86%
Inst Own
85.26%
Inst Trans
1.07%
ROA
-39%
ROE
-58%
ROC
-0.46%
Gross Margin
97%
Oper. Margin
-384%
Profit Margin
-356%
Payout
-
Shs Outstand
37.5M
Shs Float
28.19M
-
-
-
-
Target Price
-
52W Range
11.33-40.4
52W High
-7.62%
52W Low
+235.91%
RSI
60
Rel Volume
0.6
Avg Volume
787.72K
Volume
469.63K
Perf Week
9.58%
Perf Month
17.12%
Perf Quarter
110.3%
Perf Half Y
126.13%
-
-
-
-
Beta
1.072
-
-
Volatility
1.08%, 2.71%
Prev Close
6.88%
Price
36.95
Change
9.97%

TARS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
002.771.050.59
Net income per share
-1.98-4.32-0.67-2.52-4.62
Operating cash flow per share
-1.55-3.410.18-1.99-4
Free cash flow per share
-1.63-3.480.15-2.01-4.19
Cash per share
24.5327.098.368.827.74
Book value per share
-2.5426.748.117.846.7
Tangible book value per share
-2.5426.748.117.846.57
Share holders equity per share
-2.5426.748.117.846.7
Interest debt per share
0.090.160.090.911.14
Market cap
48.63M256.55M462.47M360.92M595.01M
Enterprise value
-9.16M89.25M293.03M309.42M401.8M
P/E ratio
-10.41-9.57-33.45-5.81-4.38
Price to sales ratio
008.1113.9834.1
POCF ratio
-13.24-12.14123.39-7.36-5.06
PFCF ratio
-12.64-11.88146.26-7.29-4.84
P/B Ratio
-8.11.552.771.873.02
PTB ratio
-8.11.552.771.873.02
EV to sales
005.1411.9923.03
Enterprise value over EBITDA
2.33-3.32-27.7-5.23-2.82
EV to operating cash flow
2.49-4.2278.18-6.31-3.42
EV to free cash flow
2.38-4.1392.67-6.25-3.27
Earnings yield
-0.1-0.1-0.03-0.17-0.23
Free cash flow yield
-0.08-0.080.01-0.14-0.21
Debt to equity
-0.030.010.010.10.15
Debt to assets
000.010.090.11
Net debt to EBITDA
14.76.2216.020.871.36
Current ratio
70.8531.6815.3314.616.93
Interest coverage
-107.45-143.610-28.52-42.78
Income quality
0.790.79-0.270.790.86
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000.451.740
Research and developement to revenue
000.731.652.88
Intangibles to total assets
00000.01
Capex to operating cash flow
0.050.02-0.160.010.05
Capex to revenue
00-0.01-0.02-0.32
Capex to depreciation
-4.73-4.75-1.88-1.56-6.27
Stock based compensation to revenue
000.150.521.14
Graham number
10.6350.9811.0821.0926.41
ROIC
0.76-0.16-0.07-0.29-0.63
Return on tangible assets
-0.08-0.16-0.08-0.27-0.52
Graham Net
-2.6826.127.777.65.89
Working capital
57.21M165.27M164.47M209.95M219.19M
Tangible asset value
-6.01M165.98M166.73M192.9M193.12M
Net current asset value
-6.29M164.66M163.78M190.41M186.89M
Invested capital
-0.030.010.010.10.15
Average receivables
20K28K56K1.84M10.65M
Average payables
315.5K1.35M5.46M9.3M14.03M
Average inventory
10K10K02.38M3.93M
Days sales outstanding
000.5950.64370.59
Days payables outstanding
2.25K3.32K1.53K3.79K4.16K
Days of inventory on hand
98.65001.82K711.9
Receivables turnover
00619.867.210.98
Payables turnover
0.160.110.240.10.09
Inventory turnover
3.7000.20.51
ROE
0.78-0.16-0.08-0.32-0.69
Capex per share
-0.07-0.07-0.03-0.02-0.19

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.410.090.570.060.41
Net income per share
-0.53-0.82-1.17-1.28-1.31
Operating cash flow per share
-0.44-0.83-0.89-1.06-1.23
Free cash flow per share
-0.45-0.84-0.92-1.2-1.11
Cash per share
8.827.566.658.067.12
Book value per share
7.846.525.516.986.17
Tangible book value per share
7.846.525.516.856.05
Share holders equity per share
7.846.525.516.986.17
Interest debt per share
0.850.970.960.960.98
Market cap
360.92M334.52M484.56M544.16M646.87M
Enterprise value
309.42M293.04M402.83M347.62M453.66M
P/E ratio
-6.9-3.82-3.86-3.48-3.86
Price to sales ratio
36.09133.8131.72290.8449.47
POCF ratio
-33.19-15.23-20.34-16.81-16.45
PFCF ratio
-32.81-14.99-19.69-14.81-18.31
P/B Ratio
1.871.933.282.553.28
PTB ratio
1.871.933.282.553.28
EV to sales
30.94117.2226.37185.7934.69
Enterprise value over EBITDA
-23.83-12.94-13.22-8.49-10.29
EV to operating cash flow
-28.46-13.34-16.91-10.74-11.53
EV to free cash flow
-28.13-13.13-16.37-9.46-12.84
Earnings yield
-0.04-0.07-0.06-0.07-0.06
Free cash flow yield
-0.03-0.07-0.05-0.07-0.05
Debt to equity
0.10.150.170.140.15
Debt to assets
0.090.120.130.110.11
Net debt to EBITDA
3.971.832.684.84.38
Current ratio
14.6115.7412.4311.156.93
Interest coverage
-21.76-36.48-40.2747.71-44.94
Income quality
0.80.940.760.830.94
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.466.041.3316.215.02
Research and developement to revenue
14.940.826.471.02
Intangibles to total assets
0000.010.01
Capex to operating cash flow
0.010.020.030.14-0.1
Capex to revenue
-0.01-0.14-0.05-2.340.31
Capex to depreciation
-1.3-3.27-4.32-17.9311.53
Stock based compensation to revenue
0.371.560.342.810.42
Graham number
9.6810.9812.0514.1713.49
ROIC
-0.07-0.12-0.03-0.16-0.34
Return on tangible assets
-0.06-0.1-0.17-0.15-0.16
Graham Net
7.56.215.126.435.42
Working capital
209.95M195.39M168.71M236.03M219.19M
Tangible asset value
192.9M173.4M147.73M209.7M193.12M
Net current asset value
190.41M170.84M142.28M204.61M186.89M
Invested capital
0.10.150.170.140.15
Average receivables
3.8M3.25M1.58M3.31M12.04M
Average payables
7.75M9.48M8.61M9.28M14.27M
Average inventory
0-209K-209K7.5K1.56M
Days sales outstanding
32.24105.051.45306.41121.92
Days payables outstanding
2.23K3.19K2.33K2.48K1.34K
Days of inventory on hand
0-147.5303.58229.96
Receivables turnover
2.790.8662.10.290.74
Payables turnover
0.040.030.040.040.07
Inventory turnover
0-0.61025.130.39
ROE
-0.07-0.13-0.21-0.18-0.21
Capex per share
-0.01-0.01-0.03-0.140.13

TARS Frequently Asked Questions

What is Tarsus Pharmaceuticals, Inc. stock symbol ?

Tarsus Pharmaceuticals, Inc. is a US stock , located in Irvine of Ca and trading under the symbol TARS

What is Tarsus Pharmaceuticals, Inc. stock quote today ?

Tarsus Pharmaceuticals, Inc. stock price is $36.95 today.

Is Tarsus Pharmaceuticals, Inc. stock public?

Yes, Tarsus Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap